1. Baronas, E.T., Lee, J.W., Alden, C. and Hsieh, F.Y. (2007): Biomarkers to monitor drug-induced phospholipidosis. Toxicol. Appl. Pharmacol., 218, 72-78.
2. Bligh, E.G. and Dyer, W.J. (1959): A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol., 37, 911-917.
3. Buck, A., Halbritter, S., Späth, C., Feuchtinger, A., Aichler, M., Zitzelsberger, H., Janssen, K.-P. and Walch, A. (2015): Distribution and quantification of irinotecan and its active metabolite SN-38 in colon cancer murine model systems using MALDI MSI. Anal. Bioanal. Chem., 407, 2107-2116.
4. Buratta, S., Urbanelli, L., Ferrara, G., Sagini, K., Goracci, L. and Emiliani, C. (2015): A role for the autophagy regulator Transcription Factor EB in amiodarone-induced phospholipidosis. Biochem. Pharmacol., 95, 201-209.
5. Delaney, J., Neville, W.A., Swain, A., Miles, A., Leonard, M.S. and Waterfield, C.J. (2004): Phenylacetylglycine, a putative biomarker of phospholipidosis: its origins and relevance to phospholipid accumulation using amiodarone treated rats as a model. Biomarkers, 9, 271-290.